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Background. Apolipoprotein A-IV (ApoA-IV) is a 46 kD
glycoprotein thought to protect against atherosclerosis. It is
synthesized primarily in epithelial cells of the small intestine.
Elevated plasma concentrations of ApoA-IV in patients with
chronic kidney disease suggest that the human kidney is in-
volved in ApoA-IV metabolism.
Methods. To investigate whether the human kidney directly
metabolizes ApoA-IV and which kidney tissue compartment
is involved therein, ApoA-IV was localized by immunohisto-
chemistry in 28 healthy kidney tissue samples obtained from pa-
tients undergoing nephrectomy. ApoA-IV mRNA expression
was analyzed by real-time polymerase chain reaction (PCR) to
exclude de novo synthesis in the kidney.
Results. ApoA-IV immunostaining was detected in proximal
and distal tubular cells, capillaries and blood vessels but not in-
side glomeruli. ApoA-IV was predominantly found in the brush
border of proximal tubules and in intracellular granules and
various plasma membrane domains of both proximal and distal
tubules. mRNA expression analysis revealed that no ApoA-IV
was produced in the kidney.
Conclusion. The immunoreactivity of ApoA-IV observed in
kidney tubular cells suggests a direct role of the human kidney
in ApoA-IV metabolism. The granular staining pattern proba-
bly represents lysosomes degrading ApoA-IV. The additional
ApoA-IV localization in distal tubules suggests a rescue func-
tion to reabsorb otherwise escaping ApoA-IV in case prox-
imal tubules cannot reabsorb all ApoA-IV. Since no mRNA
expression could be detected in any kidney cells, the observed
ApoA-IV immunoreactivity represents uptake and not de novo
synthesis of ApoA-IV.
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Human apolipoprotein A-IV (ApoA-IV) is a 46 kD
plasma glycoprotein synthesized by the small intestine
and to a much smaller extent by the liver [1, 2]. Mean
plasma concentrations of ApoA-IV in humans are about
15 mg/dL. Studies in rats showed that ApoA-IV is re-
leased by the small intestine into the mesenteric lymph
and enters the plasma compartment as a structural
protein of chylomicrons, very low-density lipoproteins
(VLDL), high-density lipoproteins (HDL), or unassoci-
ated with lipoproteins [3–5]. Although most glycopro-
teins have relatively long half-lives in plasma, human
ApoA-IV is among the apolipoproteins with the high-
est turnover rates [6]. Reports on the distribution of
ApoA-IV in human plasma are contradictory. Depend-
ing on the used technique they describe ApoA-IV distri-
butions ranging from ApoA-IV almost entirely bound to
HDL to mostly unassociated with major lipoprotein frac-
tions [1, 7–11]. We recently prepared lipoprotein fractions
with mild separation techniques to analyze and quantify
ApoA-IV in three different plasma fractions: lipid-free
ApoA-IV (4%), ApoA-IV associated with apolipopro-
tein A-I (ApoA-I) (12%), and ApoA-I-unbound but
lipoprotein-containing ApoA-IV (84%) [12].
Since its discovery in 1974 [13], various physiologic
functions have been proposed for this apolipoprotein.
Numerous in vitro studies suggested that it participates
in several steps of the reverse cholesterol transport path-
way, which removes and transports cholesterol from pe-
ripheral cells to the liver or steroidogenic organs for
final conversion into bile acids or hormones [10, 14, 15].
ApoA-IV enhances the formation of small HDL particles
by activating the enzyme lecithin cholesterol acyltrans-
ferase (LCAT) [15–17]. It also modulates the activation
of lipoprotein lipase [18, 19] and the cholesteryl ester
transfer protein (CETP)-mediated transfer of cholesteryl
esters from HDL to LDL in in vitro studies [20, 21]. In
line with these in vitro data, overexpression of ApoA-IV
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in transgenic mice led to reduced aortic lesions and pro-
tection against atherosclerosis [22, 23]. These results were
recently confirmed by case-control studies in three inde-
pendent human populations: ApoA-IV plasma concen-
trations were found to be significantly lower in patients
with coronary artery disease as compared to control
groups [24, 25]; a correlation between plasma ApoA-IV
concentrations and atherosclerosis was also observed in
patients with kidney failure [26].
Several studies suggest a role of the kidney in
metabolism of ApoA-IV. Patients with chronic kidney
disease exhibit markedly elevated ApoA-IV concentra-
tions [27–30]. ApoA-IV starts to increase already in the
earliest phases of kidney insufficiency, which identifies
ApoA-IV as an early marker of kidney impairment [26].
To our knowledge only one study in rats investigated
sites of ApoA-IV catabolism [31]. Although the liver was
found to be the major site of degradation, the kidney
contributes significantly to catabolism of ApoA-IV. No
study has been performed in the human kidney to date. It
was therefore the aim of this work to localize ApoA-IV in
normal human kidney tissue in order to better understand
the role of the kidney in ApoA-IV metabolism.
METHODS
Subjects
Human kidney tissue and blood samples from 28 pa-
tients (11 male and 17 female, mean age 64, range 19 to
80 years) were included in this study. The study was ap-
proved by the Ethics Committee of the Innsbruck Med-
ical University. All patients were undergoing total uni-
lateral nephrectomy due to kidney cell carcinoma (N =
20), chronic pyelonephritis (N = 3), chronic interstitial
nephritis (N = 1), oncocytoma (N = 2), or angiosarcoma
(N = 1). None of the patients had severe proteinuria (the
dipstick test for proteinuria was 1+ positive at most).
One kidney sample was obtained from the Department
of Forensic Medicine from a deceased person in whom
the autopsy was performed 3 hours after death. Histo-
logic investigation revealed that in 13 of the 20 kidney
cell carcinoma kidneys the tumor was growing still encap-
sulated. In seven cases infiltrating growth was observed.
In all cases, only healthy parts of the kidney cortex were
used for histologic investigation.
A blood sample was taken after overnight fasting prior
to surgery. Ethylenediaminetetraacetic acid (EDTA)
plasma was obtained after low-speed centrifugation at
4◦C and frozen at -80◦C prior to use. It was ensured that
patients did not undergo any examination with contrast
agents up to 1 week before blood donation, which could
influence kidney function.
Measurement of plasma ApoA-IV concentration
Plasma ApoA-IV concentrations were determined
using a double-antibody enzyme-linked immunosorbent
assay (ELISA), which employs an affinity-purified poly-
clonal antihuman ApoA-IV antibody for coating and the
same antibody coupled to horseradish peroxidase for de-
tection. Plasma with known content of ApoA-IV served
as calibration standard. The lower detection limit of this
assay is 0.002 mg/dL [32]. Each sample was analyzed in
duplicate. The affinity-purified antibody was prepared
by immunoadsorption chromatography of rabbit antihu-
man ApoA-IV antiserum using purified plasma ApoA-
IV coupled to cyanogen bromide–activated sepharose 4B
(Amersham Pharmacia Biotech AB, Uppsala, Sweden).
Antiserum was obtained by immunizing rabbits with pu-
rified plasma ApoA-IV [29, 32, 33].
Tissue preparation
Kidney tissue was cut into pieces approximately 1 mm3
in size immediately after nephrectomy and fixed in
4% paraformaldehyde in Hepes buffer (pH 7.0). After
24 hours, tissue was rinsed in phosphate-buffered saline
(PBS) and embedded in paraffin wax after a standard
alcohol dehydration protocol and infiltration with ben-
zoic methyl ester and benzene. Tissue sections, 5 to 7 lm
thick, were cut with a Reichert Autocut 2040 microtome
(Leica, Vienna, Austria) and mounted on coated glass
slides (ChemMate Capillary Gap Microscope Slides)
(Dako, Glostrup, Denmark). For the purpose of demon-
strating colocalization with a distal tubular marker, pairs
of 5 to 7 lm thick neighboring sections were cut.
Immunohistochemistry
Tissue sections were incubated in xylene, rehydrated
via graded ethanol series to water, and treated overnight
with 0.1 mol/L citrate buffer antigen retrieval solution
(pH 6.0) (Dako) at 85◦C to retrieve antigen exposure.
Endogenous peroxidase was blocked with 3% H2O2 for
5 minutes. Nonspecific binding was blocked by incuba-
tion in 1% BSA (fraction V) (Sigma) in 0.01 mol/L Tris-
HCl buffer (pH 8.6) with 0.01% Triton X-100 (BSA-T) at
room temperature for 1 hour. Affinity-purified polyclonal
rabbit antihuman ApoA-IV antibody (0.8 mg/mL) (see
ELISA protocol), diluted 1:800 in BSA-T and commer-
cially available (Biotrend Chemikalien GmbH, Cologne,
Germany) polyclonal rabbit anti-Tamm-Horsfall glyco-
protein (immunoglobulin fraction, 15 mg/mL, diluted
1:500 in BSA-T), served as primary antibodies and were
applied for 1 hour at room temperature. Excessive, un-
bound primary antibody was removed by washing with
Tris-HCl buffer. Specific immunoreaction was detected
using a secondary horseradish peroxidase–conjugated
goat antirabbit antibody (EnVision System) (Dako). In-
cubation with the secondary antibody was performed
as recommended by the manufacturer. After washing
in Tris-HCl buffer, 3-3′-diaminbenzidine tetrahydrochlo-
ride (DAB+) (Dako) was used for visualization. Sec-
tions were counterstained with hematoxylin, dehydrated,
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and mounted in DePeX (Serva, Heidelberg, Germany)
and examined with a Reichert Polyvar microscope (Le-
ica). Images were taken with a Penguin 600 CL (Pixera
Corporation, Los Gatos, CA, USA) digital camera using
Viewfinder for image processing. One section from each
sample was incubated with antibody-adsorbed antiserum
(corresponding to the unbound fraction of immunoad-
sorption chromatography) (see ELISA protocol above)
instead of the primary antibody and served as control.
Cell culture
Primary normal human mesangial cells, normal hu-
man kidney proximal tubular cells, and recommended
culture media were obtained from Cambrex BioScience
(Verviers, Belgium). Cells were cultured according to the
manufacturer’s instructions at 37◦C in 5% CO2. Mesan-
gial cell basal medium was supplemented with 5% fe-
tal calf serum (FCS), 50 mg/L gentamicin, and 50 lg/L
amphotericin B. Renal epithelial cell basal medium was
supplemented with 5% FCS, 10 lg/L human recombi-
nant epidermal growth factor (hEGF), 5 mg/L insulin,
0.5 mg/L hydrocortisone, 0,5 mg/L epinephrine, 7 lg/L
triiodothyronine, 10 mg/L transferrin, 50 mg/L gentam-
icin, and 50 lg/L amphotericin B. Cells were subcultured
at 70% to 90% confluency and were in sixth passage when
used for isolation of total RNA.
The human hepatocarcinoma cell line HepG2 was cul-
tured in essential medium [Dulbecco’s modified Eagle’s
medium (DMEM)] with high glucose supplemented with
10% FCS, 2 mmol/L L-glutamine, 100 units/mL peni-
cillin, and 100 lg/mL streptomycin. Cells were main-
tained in 5% CO2 at 37◦C and subcultured at 70% to
90% confluency.
Isolation of total RNA and protein from the human
kidney tissue and cell culture
Frozen human kidney tissue and primary normal hu-
man mesangial cells, normal human kidney proximal
tubular cells and HepG2 cells were transferred to a tube
containing ice-cold Tri Reagent (Molecular Research
Center, Inc., Cincinnati, OH, USA). Total RNA and pro-
tein isolation followed a protocol recommended by the
manufacturer. Isolated total RNA was stored at −80◦C
and proteins at −20◦C. Total RNA from cells in cell cul-
ture was used for ApoA-IV expression analysis, and iso-
lated proteins from human kidney tissue for analyzing
antibody specificity.
Immunoblot analysis
Immunoblot analysis of ApoA-IV was performed
on samples separated by sodium dodecyl sulfate-
polyacrylamide gel electrophoresis (SDS PAGE) and
transferred to cellulose nitrate membranes. Purified
ApoA-IV was used as standard. ApoA-IV was isolated
from human plasma by lipoprotein depletion, followed
by incubation with a triglyceride-phospholipid emul-
sion and separation of hydrophobic, lipid-bound pro-
teins by anion-exchange chromatography [33]. The same
affinity-purified, horseradish peroxidase–labeled antihu-
man ApoA-IV that was included in the ELISA protocol
was also used for immunoblotting.
Quantification of ApoA-IV mRNA by real-time
polymerase chain reaction (PCR)
Purity and integrity of the extracted RNA were as-
certained with the RNA 6000 Nano LabChip reagent
set using an Agilent 2100 Bioanalyzer (Agilent Tech-
nologies, Palo Alto, CA, USA). Human total RNA
samples were obtained from Clontech (BD Biosciences
Clontech, Mountain View, CA, USA). The RNA was
quantified spectrophotometrically and then stored at –
80◦C. First-strand cDNA synthesis was performed with
the Reverse Transcription System (Promega, Madison,
WI, USA) using a protocol previously described [34].
TaqMan PCR assays were performed on an ABI Prism
7900 HT Sequence Detection System (Perkin Elmer
Applied Biosystems, Darmstadt, Germany) [34] us-
ing an ApoA-IV Assay-on-Demand (Hs00166636 m1)
(Applied Biosystems, Darmstadt, Germany) overlapping
the exon2/exon3 boundary. Normalization of samples was
performed with the housekeeper 18S RNA.
Statistical evaluation
We compared continuous variables between patients
with and without immunostaining in distal tubules us-
ing the Mann-Whitney U test. Categorical variables were
compared with Fisher’s exact test.
RESULTS
Specificity of ApoA-IV antibody
In order to verify the specificity of polyclonal rabbit an-
tihuman ApoA-IV antibody used for immunohistochem-
istry we tested the antibody by immunoblotting analysis
on human kidney protein isolated from tissues from two
different patients and corresponding plasma samples. As
shown in Figure 1, ApoA-IV antibody was able to de-
tect only one protein band in tissue and plasma samples,
but a double band in the ApoA-IV preparation, which
served as standard. Peptide sequencing confirmed that
both protein bands of the standard represent ApoA-IV.
The second, smaller apoA-IV isoform might therefore
result from deglycosylation or proteolytic degradation.
Localization of ApoA-IV in the human kidney tissue
ApoA-IV was localized by immunostaining using
affinity-purified polyclonal rabbit anti-ApoA-IV anti-
body (Fig. 2). A strong and distinct staining was observed
in proximal tubules and in about half of the patients in dis-
tal tubules (although with weaker intensity) (Fig. 2A to C,
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Apo A-IV
Fig. 1. Immunoblot analysis of apolipoprotein A-IV (ApoA-IV) show-
ing specificity of polyclonal rabbit antihuman apoA-IV antibody used
for immunohistology. Proteins from human kidney tissue from patient
1 (A) and patient 2 (B), ApoA-IV preparation as standard (C) and
plasma from patient 1 (D) and patient 2 (E).
E, and H). Distal tubules were identified by immunostain-
ing using a polyclonal rabbit anti-Tamm-Horsfall glyco-
protein (uromucoid) antibody. This protein is exclusively
expressed in renal epithelial cells of the thick ascend-
ing limb of the Loop of Henle and distal tubular cells
[35] and thus serves as highly specific marker for the
thick ascending limb and distal tubules. To demonstrate
colocalization, pairs of neighboring sections were cut
and stained with antibodies against either ApoA-IV or
Tamm-Horsfall protein (Fig. 2D, E, G, and H). Patients
with positive immunostaining in distal tubules did not
differ significantly with respect to any of the variables
presented in Table 1. Interestingly, ApoA-IV plasma con-
centrations were generally lower (6.7 ± 4.3 mg/dL, range
2.3 to 17.4 mg/dL) as compared to the general population.
Staining in proximal tubules was found predominantly
in the brush border, but also in various domains of the
plasma membrane and as distinct intracellular granular
pattern (Fig. 2A and B). In distal tubules, staining ap-
peared as typical granular pattern, sometimes diffuse in
cytoplasm and also on membranes (Fig. 2C, E, and H).
Staining in capillaries of glomeruli and the juxtaglomeru-
lar apparatus between tubules and in blood vessels oc-
curred very rarely and weakly. No difference in staining
intensity was seen between subjects. No positive stain-
ing was ever observed in mesangial cells of glomeruli
(Fig. 2F). The controls obtained using antibody-adsorbed
antiserum instead of the primary antibody did not show
any evidence of nonspecific staining (Fig. 2I).
Expression analysis of ApoA-IV
The mRNA level of ApoA-IV was measured in human
kidney tissue as a whole and in mesangial and tubular
cells. ApoA-IV expression was found neither in human
kidney tissue nor in primary normal human mesangial
or proximal tubular cells (Table 2). In a control ex-
periment, mRNA of liver tissue and HepG2 cells with
known ApoA-IV expression (described earlier [1]) was
investigated and revealed abundant mRNA expression
of ApoA-IV.
DISCUSSION
We here report for the first time the localization of
ApoA-IV in proximal and distal tubules of normal hu-
man kidney tissue. In proximal tubules, ApoA-IV was
found predominantly in the brush border but also in baso-
lateral and basement membranes, intracellular granules,
and, very rarely, diffuse in cytoplasm. Previous studies in
rats suggested that small fractions of ApoA-I and ApoA-
IV are rapidly filtered by glomeruli, then endocytosed
and degraded in epithelial cells of proximal tubules [31,
36, 37]. Similar to the observation in our study, ApoA-IV
was localized in granules in cells from proximal tubules
of leupeptin-treated rats. Injection of leupeptin, an in-
hibitor of lysosomal proteolytic degradation, resulted in
a specific increase in intracellular granular staining. Those
findings indicated that degradation of ApoA-IV in the rat
kidney occurs in lysosomes of epithelial cells of proximal
tubules [31].
Our finding of one intact protein band in kidney tis-
sue corresponding to ApoA-IV (Fig. 1), suggests that
substantial amounts of ApoA-IV are taken up by prox-
imal tubular cells and are not degraded intracellularly.
This pathway could serve to rescue glomerularly fil-
tered ApoA-IV either for return to the circulation or to
serve other intracellular functions. Such rescue transport
in proximal tubular cells has been described for other
plasma molecules such as vitamin B12 and retinol [38] as
well as ApoA-I [39]. It was demonstrated that ApoA-I
and HDL bind to cubilin in vitro and that ApoA-I is taken
up by proximal tubules in rats in vivo [39]. HDL/HDL
apolipoproteins may traffic via at least two pathways af-
ter cubilin-mediated endocytosis, one that leads to lyso-
somal degradation and another that leads out of the cell
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Fig. 2. Immunoreactivity of apolipoprotein A-IV (ApoA-IV) in normal human kidney tissue. The overview panel (A) shows immunostaining in
proximal and (much weaker) in distal tubules. In proximal tubules a strong staining was observed in the brush border, in intracellular granules,
and on basolateral membranes (B). In distal tubules signals were detected in intracellular granules, on basolateral membranes and faintly in the
cytoplasm (C). No staining was observed in the glomeruli (F). The control experiment with antibody-absorbed antiserum showed no staining as
well (I). Immunostaining was observed with antibodies to ApoA-IV and Tamm-Horsfall glycoprotein, a specific marker for distal tubules, in two
pairs of neighbouring sections (D, E, G, and H) thus confirming ApoA-IV localization in distal tubules. Abbreviations are: C, collecting tubule; D,
distal tubule; G, glomerulum; P, proximal tubule; arrowhead, brush border; arrow, basolateral membrane and asterisk, intracellular granule. Bars
(A, D, E, and F), 20 lm; (B, C, G, H, and I), 10 lm.
(e.g., transcytosis). HDL/HDL apolipoproteins may per-
haps follow a process in which HDL particles and/or
apolipoprotein constituents bypass degradation and are
delivered to the blood for reutilization [40]. This process
may be similar to “retroendocytosis” of HDL in which in-
ternalization is followed by unloading of the cholesteryl
ester and retrograde secretion of the lipid-depleted par-
ticle [41]. The absence of degradation products of ApoA-
IV in kidney tissue (Fig. 1) does, however, not exclude an
at least partial degradation of ApoA-IV in the kidney;
intact ApoA-IV could also originate from endosomes in
which degradation has not taken place. Further investi-
gations are necessary to elucidate the origin and function
of the ApoA-IV–containing granules in tubular cells that
were detected in our work.
Apart from proximal tubules, we also localized ApoA-
IV in distal tubules and, occasionally, with very weak
staining in blood vessels and capillaries. As in proximal
tubules, immunostaining was observed in intracellular
granules but also in basolateral domains of the plasma
membrane. The physiologic significance of this latter find-
ing remains to be elucidated but indicates again that
ApoA-IV is certainly not completely degraded after up-
take in kidney cells. Alternatively, this basolateral stain-
ing might also represent circulating ApoA-IV diffusing
out of peritubular capillaries. We statistically evaluated
the staining in distal tubules in relation to various param-
eters (Table 1) and did not find any significant correlation.
We therefore speculate that when proximal tubules can-
not reabsorb all ApoA-IV, distal tubules have a rescue
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Table 1. Characteristics of patients depending on apolipoprotein
A-IV (ApoA-IV) staining in distal tubules
ApoA-IV staining in distal tubules
Positive (N = 13) Negative (N = 15) P value
Age years 65 ± 12 64 ± 16 0.93
Female gender% 77 47 0.14
Current smokers%a 0 29 0.10
Body mass indexb 24.4 ± 6.0 24.8 ± 3.8 0.60
Diabetes%b 0 14.3 0.48
Hypertension%b 30.8 21.4 0.68
ApoA-IV mg/dL 5.4 ± 2.6 7.8 ± 5.1 0.32
Plasma creatinine 1.20 ± 0.29 1.20 ± 0.27 0.87
mg/dLb
Urea mg/dLb 39.9 ± 30.8 36.0 ± 13.3 0.69
GOTb units/L 13.0 ± 12.5 9.8 ± 3.6 1.00
GPTb units/L 13.5 ± 14.9 10.5 ± 5.2 0.94
GGTb units/L 26.5 ± 38.2 19.2 ± 11.5 0.65
Abbreviations are: GOT, glutamate oxalacetate transaminase; GPT, glutamate
transaminase; GGT, gamma glutamyltransferase.
aStatus in two patients not known; bStatus in one patient not known.
Table 2. Relative concentration of apolipoprotein A-IV (ApoA-IV)
mRNA in various samples (values show expression relative to human
liver)
ApoA-IV
Sample expression
Human liver (Clontech) 1.0
HepG2 55.0
Human kidney (Clontech) 0.0
Normal human kidney tissue 1 0.0
Normal human kidney tissue 2 0.0
Primary normal human mesangial cells 0.0
Primary normal human kidney proximal tubular cells 0.0
function to reabsorb the remaining and otherwise escap-
ing ApoA-IV. In fact, such functions of the distal tubu-
lar system have been described for other proteins in the
past [42]. The colocalization of Apo A-IV with Tamm-
Horsfall protein which is mainly expressed in the thick
ascending limb [35] suggests the localization of ApoA-
IV in the thick ascending limb in addition to the distal
tubule as well.
Under physiologic conditions the physicochemical
properties of HDL (size, shape, charge) restrict their pas-
sage through the glomerulus. Small-sized HDL subfrac-
tions with a diameter of up to 8 nm and lipid-free or
lipid-poor apolipoproteins are filtered in the glomerulus,
entirely reabsorbed in the proximal tubules and unde-
tectable in the urine [43–45]. We therefore assume that,
for reasons of particle size, large ApoA-IV–containing
lipoprotein particles are highly unlikely to be filtered
in the glomeruli and reach tubular cells for uptake.
The tubular immunostaining observed in the present
work thus probably represents uptake of lipoprotein-free
ApoA-IV.
mRNA expression analysis demonstrated that no
ApoA-IV was produced in the kidney by comparison with
the amount produced in the liver (Table 2). We therefore
conclude that the observed ApoA-IV staining in proxi-
mal and distal tubules represents ApoA-IV uptake and
not de novo synthesis by kidney cells.
We speculate that the lower ApoA-IV plasma concen-
trations observed in our patient group (6.7 ± 4.3 mg/dL,
range 2.3 to 17.4 mg/dL) are due to catabolic conditions
of wasting disease in the patients. The usually observed
mean ApoA-IV level in the general population measured
with our assay is substantially higher (13 to 15 mg/dL) [24,
30].
CONCLUSION
Our results lead us to conclude that ApoA-IV is taken
up primarily by proximal tubules and that the human
kidney plays an important role in the metabolism of
ApoA-IV.
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